Therapeutic Classification: antiplatelet agents
Pharmacologic Classification: glycoprotein iib iiia inhibitors
Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism/Excretion: 50% excreted by the kidneys.
Half-life: 2.5 hr.
(effects on platelet function)
†Inhibition is reversible following cessation of infusion.
Noted for patients receiving heparin and aspirin in addition to eptifibatide
CV: hypotension.
Hemat: BLEEDING (INCLUDING GI AND INTRACRANIAL BLEEDING, HEMATURIA, AND HEMATOMAS), thrombocytopenia.
Acute Coronary Syndrome
- IV (Adults): 180 mcg/kg (max = 22.6 mg) as a bolus dose, followed by 2 mcg/kg/min (max = 15 mg/hr) infusion until hospital discharge or initiation of coronary artery bypass graft surgery (up to 72 hr). If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18–24 hr after the PCI, whichever comes first, allowing for up to 96 hr of therapy.
Renal Impairment
- IV (Adults): CrCl <50 mL/min: 180 mcg/kg (max = 22.6 mg) as a bolus dose, followed by 1 mcg/kg/min (max = 7.4 mg/hr) infusion until hospital discharge or initiation of coronary artery bypass graft surgery (up to 72 hr). If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18–24 hr after the PCI, whichever comes first, allowing for up to 96 hr of therapy.
Percutaneous Coronary Intervention
- IV (Adults): 180 mcg/kg (max = 22.6 mg) as a bolus dose, immediately before PCI, followed by 2 mcg/kg/min (max = 15 mg/hr) infusion; a 2nd bolus of 180 mcg/kg (max = 22.6 mg) is given 10 min after 1st bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hr, whichever comes first (minimum of 12 hr).
Renal Impairment
(Adults): CrCl <50 mL/min: 180 mcg/kg (max = 22.6 mg) bolus followed by 1 mcg/kg/min (max = 7.4 mg/hr) infusion; a 2nd bolus of 180 mcg/kg (max = 22.6 mg) is given 10 min after 1st bolus.
4 mg/dL) or dependency on renal dialysis.